TG Therapeutics (TGTX): Exploring Valuation After Raised Guidance and Strong Q3 Financial Results

TG Therapeutics (TGTX) delivered a strong set of third-quarter results, with revenue and net income showing substantial increases compared to last year. The company also raised its full-year global revenue target, which signals growing confidence in its business momentum.

See our latest analysis for TG Therapeutics.

Following a string of upbeat announcements, including positive trial updates and a raised revenue outlook, TG Therapeutics’ momentum is showing up in its numbers. While the share price recently dipped from highs, the stock still boasts a 20.7% gain over the past 90 days and an impressive 11.9% total shareholder return in the last year, demonstrating solid long-term performance despite some recent volatility.

If strong biotech results have caught your eye, you might want to discover new opportunities with our curated healthcare stocks screener: See the full list for free.

With shares trading below analyst targets despite strong financials and recent guidance upgrades, the question for investors becomes clear: is TG Therapeutics undervalued at current levels, or has the market already priced in further growth?

Most Popular Narrative: 27.2% Undervalued

Compared to TG Therapeutics' last close at $32.24, the most popular narrative estimates fair value at $44.29. This sizable gap sets the stage for a deeper examination of the driving catalysts behind such optimism.

The planned launch of subcutaneous (subcu) BRIUMVI is a significant upcoming catalyst, as it could unlock access to 35 to 40% of the anti-CD20 MS market segment currently dominated by self-administered therapies. This could greatly increase BRIUMVI's addressable market and support long-term revenue growth.

Read the complete narrative.

Curious about what bold growth assumptions justify this premium? The most popular narrative banks on a breakout in future sales, surging margins, and a profit trajectory usually reserved for sector leaders. Find out which projections and financial leaps breathe life into this valuation, one surprising number at a time.

Result: Fair Value of $44.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, heavy reliance on BRIUMVI and mounting competition from new MS therapies could quickly change the growth outlook for TG Therapeutics.

Find out about the key risks to this TG Therapeutics narrative.

Build Your Own TG Therapeutics Narrative

Not convinced by the consensus or want to dig into the numbers yourself? You can quickly build your own investment case and narrative in minutes. Do it your way

A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.

Looking for More Smart Investment Ideas?

Your next top pick could be just a click away. Uncover stocks with game-changing potential and stay ahead while others wait on the sidelines.

• Boost your income strategy and tap into reliable returns with these 16 dividend stocks with yields > 3%, which offers yields above 3% and strong company fundamentals.
• Catch the momentum in artificial intelligence by checking out these 24 AI penny stocks, leading major transformations across multiple industries.
• Spot undervalued gems primed for growth by browsing these 870 undervalued stocks based on cash flows and seize unique opportunities before they are widely recognized.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com